Moderna and Merck report successful clinical outcomes for mRNA cancer vaccine

Moderna and Merck have achieved positive clinical results for their joint mRNA-based cancer vaccine, overcoming previous skepticism and logistical hurdles. While the specific efficacy data and regulatory timeline remain to be fully detailed, the success validates the application of mRNA technology beyond infectious disease.